Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.7281
At close: May 14 EDT
$0.7269
-0.00120-0.16%
Pre-Market: 7:29 PM EDT
Comments
Loading...
iBio Analyst Ratings and Price Targets | NASDAQ:IBIO | Benzinga
iBio Inc has a consensus price target of $3.69 based on the ratings of 5 analysts. The high is $6 issued by LUCID CAPITAL MARKETS on December 17, 2024. The low is $0.17 issued by Cantor Fitzgerald on October 7, 2022. The 3 most-recent analyst ratings were released by Chardan Capital, Chardan Capital, and LUCID CAPITAL MARKETS on May 6, 2025, May 5, 2025, and December 17, 2024, respectively. With an average price target of $5.33 between Chardan Capital, Chardan Capital, and LUCID CAPITAL MARKETS, there's an implied 633.71% upside for iBio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Chardan Capital
LUCID CAPITAL MARKETS
Brookline Capital
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for iBio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/06/2025 | Buy Now | 587.85% | Chardan Capital | Keay Nakae55% | $5 → $5 | Maintains | Buy | Get Alert |
| 05/05/2025 | Buy Now | 587.85% | Chardan Capital | Keay Nakae55% | $5 → $5 | Maintains | Buy | Get Alert |
| 12/17/2024 | Buy Now | 725.42% | LUCID CAPITAL MARKETS | Dev Prasad 8% | → $6 | Initiates | → Buy | Get Alert |
| 07/22/2024 | Buy Now | 395.25% | Brookline Capital | Kemp Dolliver27% | → $3.6 | Initiates | → Buy | Get Alert |
| 06/03/2024 | Buy Now | 587.85% | Chardan Capital | Keay Nakae55% | $5 → $5 | Maintains | Buy | Get Alert |
| 05/28/2024 | Buy Now | 587.85% | Chardan Capital | Keay Nakae55% | → $5 | Initiates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | — | JMP Securities | Roy Buchanan35% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 10/07/2022 | Buy Now | -76.61% | Cantor Fitzgerald | Kristen Kluska67% | $2.5 → $0.17 | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for iBio (IBIO) stock?
The latest price target for iBio (NASDAQ:IBIO) was reported by Chardan Capital on May 6, 2025. The analyst firm set a price target for $5.00 expecting IBIO to rise to within 12 months (a possible 587.85% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for iBio (IBIO)?
The latest analyst rating for iBio (NASDAQ:IBIO) was provided by Chardan Capital, and iBio maintained their buy rating.
When was the last upgrade for iBio (IBIO)?
There is no last upgrade for iBio
When was the last downgrade for iBio (IBIO)?
The last downgrade for iBio Inc happened on February 16, 2023 when JMP Securities changed their price target from N/A to N/A for iBio Inc.
When is the next analyst rating going to be posted or updated for iBio (IBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on May 6, 2025 so you should expect the next rating to be made available sometime around May 6, 2026.
Is the Analyst Rating iBio (IBIO) correct?
While ratings are subjective and will change, the latest iBio (IBIO) rating was a maintained with a price target of $5.00 to $5.00. The current price iBio (IBIO) is trading at is $0.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
